Covaxin Works Against UK Strain, Variant Found in India: Bharat Biotech

Covaxin "produced neutralising titres (meaning the concentration of antibodies) against all key emerging variants", Bharat Biotech said.

Bharat Biotech has said its vaccine Covaxin is effective against the aggressively virulent B.1.167 strain of Covid detected in India and the UK variant of the virus B.1.1.7. The study -- conducted by India's National Institute of Virology and the Indian Council of Medical Research -- has been published in a peer-reviewed journal, Clinical Infectious Diseases. Bharat Biotech said according to the research, Covaxin "produced neutralising titres (meaning the concentration of antibodies) against all key emerging variants". Covaxin gets international recognition yet again, by scientific research data published demonstrating protection against the new variants.Yet another feather in its cap👍🏼@PMOIndia@nsitharaman@drharshvardhan@MoHFW_INDIA@ICMRDELHI@DBTIndia@doctorsoumya@BharatBiotechpic.twitter.com/AUhphvvivz Link to article published in CID - Oxford University Press.COVAXIN neutralising emerging variants. https://t.co/ZholzoDD7Fpic.twitter.com/ksiNL1kLXq "There was a modest reduction in neutralization by a factor of 1.95 was observed against B.1.617 variant compared to vaccine variant (D614G). Despite this reduction, neutralising titre levels with B.1.617 remain above levels expected to be protective," read the excerpts highlighted by Bharat Biotech. "Covaxin gets international recognition yet again, by scientific research data published demonstrating protection against the new variants. Yet another feather in its cap," tweeted Suchitra Ella, the co-founder and Joint Managing Director of Bharat Biotech.